



# BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT

**Bergen, Norway, 16 May 2022** – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ABG Sundal Collier Life Science Summit taking place on Wednesday 18 May at 11:30 CEST.

The presentation slides will be made available on the Company's website in the Investors section shortly after the presentation.

-Ends-

## Contacts

Martin Olin CEO, BerGenBio ASA  
[ir@bergenbio.com](mailto:ir@bergenbio.com)

Rune Skeie, CFO, BerGenBio ASA  
[rune.skeie@bergenbio.com](mailto:rune.skeie@bergenbio.com)  
+47 917 86 513

## International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone  
Consilium Strategic Communications  
[bergenbio@consilium-comms.com](mailto:bergenbio@consilium-comms.com)  
+44 20 3709 5700

## About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit [www.bergenbio.com](http://www.bergenbio.com)